These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32840030)

  • 1. Management of hyperkalaemia in acute kidney injury in a heart failure patient with patiromer.
    Slawik J; Dederer J; Kindermann I; Böhm M
    ESC Heart Fail; 2020 Oct; 7(5):3161-3164. PubMed ID: 32840030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer.
    Epstein M; Pitt B
    Expert Opin Pharmacother; 2016 Jul; 17(10):1435-48. PubMed ID: 27180623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life.
    Esteban-Fernández A; Ortiz Cortés C; López-Fernández S; Recio Mayoral A; Camacho Jurado FJ; Gómez Otero I; Molina M; Almenar Bonet L; López-Vilella R
    ESC Heart Fail; 2022 Oct; 9(5):3071-3078. PubMed ID: 35748119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia.
    Pitt B; Garza D
    Expert Opin Drug Saf; 2018 May; 17(5):525-535. PubMed ID: 29667438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
    Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL
    Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patiromer: a clinical review.
    Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
    Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure.
    Rossignol P; Williams B; Mayo MR; Warren S; Arthur S; Ackourey G; White WB; Agarwal R
    Eur J Heart Fail; 2020 Aug; 22(8):1462-1471. PubMed ID: 32452085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patiromer: A Review in Hyperkalaemia.
    Kim ES; Deeks ED
    Clin Drug Investig; 2016 Aug; 36(8):687-94. PubMed ID: 27380495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease].
    Degli Esposti L; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Santoro A
    G Ital Nefrol; 2019 Sep; 36(5):. PubMed ID: 31580544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world management of hyperkalemia with patiromer among United States Veterans.
    Kovesdy CP; Gosmanova EO; Woods SD; Fogli JJ; Rowan CG; Hansen JL; Sauer BC
    Postgrad Med; 2020 Mar; 132(2):176-183. PubMed ID: 31971043
    [No Abstract]   [Full Text] [Related]  

  • 11. Evolution of Patiromer Use: a Review.
    Ali W; Bakris G
    Curr Cardiol Rep; 2020 Jul; 22(9):94. PubMed ID: 32648072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
    JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Hyperkaliemia in Chronic Kidney Disease: An Old Concern with New Answers.
    Borrelli S; Matarazzo I; Lembo E; Peccarino L; Annoiato C; Scognamiglio MR; Foderini A; Ruotolo C; Franculli A; Capozzi F; Yavorskiy P; Merheb F; Provenzano M; La Manna G; De Nicola L; Minutolo R; Garofalo C
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patiromer: The First Potassium Binder Approved in Over 50 Years.
    Vu BN; De Castro AM; Shottland D; Frishman WH; Cheng-Lai A
    Cardiol Rev; 2016; 24(6):316-323. PubMed ID: 27548687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.
    Kloner RA; Gross C; Yuan J; Conrad A; Pergola PE
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):524-531. PubMed ID: 30103622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patiromer: a significant advance in the management of hyperkalemia.
    Paton DM
    Drugs Today (Barc); 2015 Dec; 51(12):695-703. PubMed ID: 26798850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperkalemia in Heart Failure.
    Sarwar CM; Papadimitriou L; Pitt B; Piña I; Zannad F; Anker SD; Gheorghiade M; Butler J
    J Am Coll Cardiol; 2016 Oct; 68(14):1575-89. PubMed ID: 27687200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
    Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
    N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapies for the management of chronic hyperkalemia in the ambulatory care setting.
    Henneman A; Guirguis E; Grace Y; Patel D; Shah B
    Am J Health Syst Pharm; 2016 Jan; 73(2):33-44. PubMed ID: 26721532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Patiromer in Hyperkalemia: A Systematic Review and Meta-Analysis.
    Das S; Dey JK; Sen S; Mukherjee R
    J Pharm Pract; 2018 Feb; 31(1):6-17. PubMed ID: 28402156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.